Excuus, deze pagina is alleen beschikbaar in het Engels.

Deal or Case news
07.08.2024
NautaDutilh advised Confo Therapeutics on its EUR 60 million Series B funding round to advance innovative therapies.

The funding round was led by new investor Ackermans & van Haaren and included other new investors like Driehaus Capital Management and Quest for Growth. Existing investors such as BioGeneration Ventures and Capricorn Health-tech Fund also continued their support. The additional funding will support early-stage clinical trials for two of their drug programmes and help advance two more programmes towards approval.

The new funding will help Confo Therapeutics develop new treatments for rare endocrine diseases and obesity, aiming to improve outcomes for patients with these conditions.
Philippe Remels, Corporate/M&A partner

About Confo Therapeutics
Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors). The company’s mission is being advanced by a team of highly experienced industry experts with extensive knowledge of the discovery and development of GPCR-directed medicines. Confo Therapeutics is headquartered in Ghent, Belgium.

Press release

  • Confotherapeutics.com: Confo Therapeutics announces EUR 60 million Series B financing to advance a pipeline of novel GPCR-modulating therapies into clinical development

Related articles

Cookie notificatie

Deze website maakt gebruik van cookies en daarmee vergelijkbare technieken om een optimale gebruikerservaring te bieden. Je kunt je voorkeuren aanpassen of meer informatie bekijken.
Deze cookies zorgen ervoor dat de website naar behoren werkt. Deze cookies kunnen niet uitgezet worden.
Deze cookies kunnen geplaatst worden door derde partijen, zoals YouTube of Vimeo.
Door categorieën uit te zetten, kan het voorkomen dat gerelateerde functionaliteiten binnen de website niet langer correct werken. Het is altijd mogelijk om op een later moment de voorkeuren aan te passen. Bekijk meer informatie.